Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Key Highlights
The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.
With five different lengths and six different French sizes,...
Key Highlights
The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.
With five different lengths and six different French sizes,...
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.
New Britain, PA, June 15, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, June 15, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
“Our study was designed to establish the evidence of a comprehensive multidisciplinary approach before considering surgical intervention,” said Dr. Richard Shi, vascular surgery resident at the Medical University of South Carolina. “Too...
“Our study was designed to establish the evidence of a comprehensive multidisciplinary approach before considering surgical intervention,” said Dr. Richard Shi, vascular surgery resident at the Medical University of South Carolina. “Too...
"The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology," said Makmood Razavi, MD.
"The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology," said Makmood Razavi, MD.
